Health, biotech and FDA headlines. Each story opens on the publisher's site.
"Feed Intelligence for Sustainable Performance" FRANKFURT, Alemania, 1 de noviembre de 2026 /PRNewswire/ -- CJ BIO participará en EuroTier 2026, que se celebrará del 10 al 13 de noviembre de 2026 en Hannover, Alemania, para presentar sus soluciones de nutrición animal a clientes y socios...
„Feed Intelligence for Sustainable Performance" FRANKFURT, Deutschland, 1. November 2026 /PRNewswire/ -- CJ BIO wird an der EuroTier 2026 teilnehmen, die vom 10. bis 13. November 2026 in Hannover stattfindet, um interessierten Kunden und Branchenpartnern seine Lösungen für die...
"Feed Intelligence for Sustainable Performance," FRANKFURT, Germany, Nov. 1, 2026 /PRNewswire/ -- CJ BIO will participate in EuroTier 2026, taking place from November 10 to 13, 2026, in Hanover, Germany, to present its animal nutrition solutions to global customers and industry partners....
"Feed Intelligence for Sustainable Performance" FRANCFORT, Allemagne, 1er novembre 2026 /PRNewswire/ -- CJ BIO participera à EuroTier 2026, qui se tiendra du 10 au 13 novembre 2026 à Hanovre, en Allemagne, afin de présenter ses solutions de nutrition animale à ses clients et partenaires...
SHANGHAI, Oct. 31, 2026 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced today that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral sclerosis (ALS), has successfully...
Un programme d'une semaine intitulé The Norns' Weave examine la pratique clinique chinoise et ses applications potentielles en Europe SHANGHAI, 30 octobre 2026 /PRNewswire/ -- aphranel®, la marque d'esthétique régénérative de MOYOM Biotech, a lancé un programme d'échange clinique amenant...
BOSTON, 30. októbra 2026 /PRNewswire/ – Dr. Yang Liu, riaditeľ oddelenia medicínskej chémie v spoločnosti Revolution Medicines, Inc., a Dr. Kristof Pota, vedúci vedecký pracovník, navštívili výskumné a vývojové centrum Nanhui spoločnosti Medicilon. Privítali ich Dr. Maosheng Duan,...
БОСТОН, 30 октября 2026 г. /PRNewswire/ -- Д-р Ян Лю (Yang Liu), директор по медицинской химии компании Revolution Medicines, Inc. и д-р Кристоф Пота (Kristof Pota), старший научный сотрудник, посетили Научно-исследовательский центр Medicilon в Наньхуэе. Д-р Маошэн Дуань (Maosheng Duan),...
INOVIO delivers a new nonsurgical treatment option with a broad indication for adults living with RRP, a rare and debilitating disease that often requires surgery VOCERYQ™ is a plasmid DNA-based immunotherapy that targets the root cause of RRP: HPV-6 and HPV-11 INOVIO expects to make...
NEW YORK, Oct. 30, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced an inducement equity award to a newly hired non-executive employee. On October 26, 2026, the...
WARREN, N.J., Oct. 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of 9.620 shares of its common stock and 11,535 restricted stock units ("RSUs"), each...
BOSTON, 30 octobre 2026 /PRNewswire/ -- Le Dr Yang Liu, directeur de la chimie médicinale chez Revolution Medicines, Inc., et le Dr Kristof Pota, scientifique principal, ont visité le centre de R&D de Medicilon à Nanhui. Le Dr Maosheng Duan, président des divisions de la découverte des...
BOSTON, 30 października 2026 r. /PRNewswire/ -- Dr Yang Liu, dyrektor ds. chemii medycznej w Revolution Medicines, Inc., oraz dr Kristof Pota, starszy naukowiec, odwiedzili Centrum Badawczo-Rozwojowe Medicilon w Nanhui. Gości powitali dr Maosheng Duan, prezes pionów odkrywania leków i...
BOSTON, Oct. 30, 2026 /PRNewswire/ -- Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research...
BOSTON, 30. října 2026 /PRNewswire/ -- Dr. Yang Liu, ředitel oddělení medicínské chemie ve společnosti Revolution Medicines, Inc., a Dr. Kristof Pota, vedoucí vědecký pracovník, navštívili výzkumné a vývojové centrum společnosti Medicilon v Nan-chuej. Přivítali je Dr. Maosheng Duan,...
BOSTON, 30. Oktober 2026 /PRNewswire/ -- Dr. YangLiu, Leiter der Abteilung für medizinische Chemie bei Revolution Medicines, Inc., und Dr. Kristof Pota, leitender Wissenschaftler, besuchten das Forschungs- und Entwicklungszentrum von Medicilon in Nanhui. Dr. Maosheng Duan, Leiter der...
BOSTON, Oct. 30, 2026 /PRNewswire/ -- Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research...
BOSTON, 30 de octubre de 2026 /PRNewswire/ -- El doctor Yang Liu, director de Química Médica de Revolution Medicines, Inc., y el doctor Kristof Pota, científico sénior, visitaron el Centro de I+D de Medicilon en Nanhui. El doctor Maosheng Duan, director general de las Divisiones de...
STOCKHOLM, October 30, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced the composition of its Nomination Committee for the 2027 Annual General Meeting. The Nomination Committee has been appointed in accordance with the principles adopted by the Annual...
STOCKHOLM, October 30, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced the composition of its Nomination Committee for the 2027 Annual General Meeting. The Nomination Committee has been appointed in accordance with the principles adopted by the Annual...